‼️ 💊 BREAKING: Eli Lilly beat estimates on resilient Zepbound and Mounjaro demand, reporting adjusted EPS of $7.48 versus $6.26 expected and revenue of $24.40 billion versus $22.61 billion forecast. It raised its 2026 revenue outlook to $91–$92 billion from $85–$87 billion, but lowered adjusted EPS guidance to $35–$36 from $35.50–$36.50, as $4.57 per share in deal-related charges more than offset a $4.07 increase in underlying profit guidance at the midpoint.
